Physician profile
David Gu
NPI 1225107006
$34,991.28
in general payments reported to CMS, 2019-2025
42 companies · $743 in 2025
The $743 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,459 · 2020: $2,982 · 2021: $6,987 · 2022: $6,314 · 2023: $5,214 · 2024: $5,292 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,140 · Food and Beverage: $4,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,140.00 |
| Food and Beverage | $4,109.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22,855.87 | 2019-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals Lp | $1,860.08 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $1,729.82 | 2019-2025 | |
| Amgen INC. | $986.75 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $736.56 | 2021-2025 | |
| Pfizer INC. | $635.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $550.18 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Cmp Pharma, INC. | $520.70 | 2021-2022 | |
| Allergan, INC. | $518.49 | 2019-2020 | |
| Amarin Pharma, INC. | $458.16 | 2019-2021 | |
| Novo Nordisk INC | $396.94 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.54 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $351.65 | 2019-2021 | |
| Radius Health, INC. | $332.42 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $309.90 | 2020-2025 | Trelegy Ellipta, Arexvy |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $287.33 | 2022-2023 | Adlarity |
| Novartis Pharmaceuticals Corporation | $249.42 | 2019-2023 | |
| Astellas Pharma US INC | $230.71 | 2019-2020 | |
| Dermavant Sciences, INC. | $203.62 | 2024 | Vtama |
| Lilly USA, LLC | $177.68 | 2020-2023 | Mounjaro, Jardiance |
| Almatica Pharma LLC | $120.32 | 2023-2024 | Loreev Xr, Teriparatide |
| Dexcom, INC. | $119.52 | 2023-2025 | Dexcom G6 Transmitter |
| Sun Pharmaceutical Industries INC. | $119.23 | 2023 | Winlevi, Ilumya |
| Abiomed | $99.98 | 2025 | |
| Biogen, INC. | $90.93 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $87.66 | 2019-2022 | |
| Vivus LLC | $85.06 | 2019-2025 | Pancreaze |
| Scilex Pharmaceuticals INC. | $67.52 | 2019-2020 | |
| Eisai INC. | $62.61 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.18 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.97 | 2019 | |
| Ironwood Pharmaceuticals, INC | $48.30 | 2024 | |
| Strata Skin Sciences, INC. | $30.78 | 2025 | Xtrac |
| Exact Sciences Corporation | $22.56 | 2025 | Cologuard Collection Kit |
| Genzyme Corporation | $21.65 | 2020 | |
| Sk Life Science, INC. | $21.50 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.10 | 2023 | Nuedexta |
| Evoke Pharma, INC. | $20.89 | 2021 | |
| Hologic Sales and Service, LLC | $20.26 | 2023 | Aptima, Thinprep 2000 Processor |
| Strongbridge US INC. | $19.32 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.93 | 2024 | |
| Genentech USA, INC. | $17.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.